931O - A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer
| Autor: | Vergote, I., Dean, E., Lassen, U., de Bono, J., Drew, Y., Machiels, J-P., Nielsen, D., Arkenau, H-T., Forster, M., Jones, R., Slomovitz, B., Spicer, J., Johnson, M., Cornez, N., Gennigens, C., Fulton, B., Lisby, S., Basse, L., Coleman, R., Hong, D.S. |
|---|---|
| Zdroj: | In Annals of Oncology September 2017 28 Supplement 5:v330-v331 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|